

14D



UNITED STATES PATENT AND TRADEMARK OFFICE

UNITED STATES DEPARTMENT OF COMMERCE
 United States Patent and Trademark Office
 Address: COMMISSIONER FOR PATENTS
 P.O. Box 1450
 Alexandria, Virginia 22313-1450
 www.uspto.gov

APPLICATION NO.	FILING DATE	FIRST NAMED INVENTOR	ATTORNEY DOCKET NO.	CONFIRMATION NO.
09/993,391	11/14/2001	Kiamars Hajizadeh	3873 P 010	4943
7590 04/26/2004				
Wallenstein & Wagner, Ltd.		EXAMINER		
53rd Floor		COUNTS, GARY W		
311 S. Wacker Drive				
Chicago, IL 60606-6622		ART UNIT	PAPER NUMBER	
		1641		
DATE MAILED: 04/26/2004				

Please find below and/or attached an Office communication concerning this application or proceeding.

Office Action Summary

Application No.

09/993,391

Applicant(s)

HAJIZADEH ET AL.

Examiner

Gary W. Counts

Art Unit

1641

-- The MAILING DATE of this communication appears on the cover sheet with the correspondence address --

Period for Reply

A SHORTENED STATUTORY PERIOD FOR REPLY IS SET TO EXPIRE 3 MONTH(S) FROM THE MAILING DATE OF THIS COMMUNICATION.

- Extensions of time may be available under the provisions of 37 CFR 1.136(a). In no event, however, may a reply be timely filed after SIX (6) MONTHS from the mailing date of this communication.
- If the period for reply specified above is less than thirty (30) days, a reply within the statutory minimum of thirty (30) days will be considered timely.
- If NO period for reply is specified above, the maximum statutory period will apply and will expire SIX (6) MONTHS from the mailing date of this communication.
- Failure to reply within the set or extended period for reply will, by statute, cause the application to become ABANDONED (35 U.S.C. § 133). Any reply received by the Office later than three months after the mailing date of this communication, even if timely filed, may reduce any earned patent term adjustment. See 37 CFR 1.704(b).

Status

- 1) ☒ Responsive to communication(s) filed on 14 November 2001.
- 2a) ☐ This action is FINAL. 2b) ☒ This action is non-final.
- 3) ☐ Since this application is in condition for allowance except for formal matters, prosecution as to the merits is closed in accordance with the practice under *Ex parte Quayle*, 1935 C.D. 11, 453 O.G. 213.

Disposition of Claims

- 4) ☒ Claim(s) 1-40 is/are pending in the application.
- 4a) Of the above claim(s) _____ is/are withdrawn from consideration.
- 5) ☐ Claim(s) _____ is/are allowed.
- 6) ☒ Claim(s) 1-40 is/are rejected.
- 7) ☐ Claim(s) _____ is/are objected to.
- 8) ☐ Claim(s) _____ are subject to restriction and/or election requirement.

Application Papers

- 9) ☒ The specification is objected to by the Examiner.
- 10) ☐ The drawing(s) filed on _____ is/are: a) ☐ accepted or b) ☐ objected to by the Examiner.
Applicant may not request that any objection to the drawing(s) be held in abeyance. See 37 CFR 1.85(a).
Replacement drawing sheet(s) including the correction is required if the drawing(s) is objected to. See 37 CFR 1.121(d).
- 11) ☒ The oath or declaration is objected to by the Examiner. Note the attached Office Action or form PTO-152.

Priority under 35 U.S.C. § 119

- 12) ☐ Acknowledgment is made of a claim for foreign priority under 35 U.S.C. § 119(a)-(d) or (f).
- a) ☐ All b) ☐ Some * c) ☐ None of:
- ☐ Certified copies of the priority documents have been received.
 - ☐ Certified copies of the priority documents have been received in Application No. _____.
 - ☐ Copies of the certified copies of the priority documents have been received in this National Stage application from the International Bureau (PCT Rule 17.2(a)).

* See the attached detailed Office action for a list of the certified copies not received.

Attachment(s)

- | | |
|--|---|
| 1) <input checked="" type="checkbox"/> Notice of References Cited (PTO-892) | 4) <input type="checkbox"/> Interview Summary (PTO-413)
Paper No(s)/Mail Date. _____ |
| 2) <input type="checkbox"/> Notice of Draftsperson's Patent Drawing Review (PTO-948) | 5) <input type="checkbox"/> Notice of Informal Patent Application (PTO-152) |
| 3) <input checked="" type="checkbox"/> Information Disclosure Statement(s) (PTO-1449 or PTO/SB/08)
Paper No(s)/Mail Date <u>3/5/02, 6/5/03, & 7/14/03</u> | 6) <input type="checkbox"/> Other: _____ |

DETAILED ACTION

Oath/Declaration

1. The oath or declaration is defective. A new oath or declaration in compliance with 37 CFR 1.67(a) identifying this application by application number and filing date is required. See MPEP §§ 602.01 and 602.02.

The oath or declaration is defective because: The residential street address, Inventor's Signature and Date of the signature for Zakir S Murtaza is obscured and unreadable.

Specification

2. The disclosure is objected to because of the following informalities:

On page 7, line 6 the specification discloses " Figure 2 is a side perspective view", however Figure 2 appears to be a top perspective view.

On page 7, line 8 the specification discloses "Figure 3 is a top schematic view", however Figure 3 appears to be a side perspective view.

Appropriate correction is required.

Claim Rejections - 35 USC § 112

3. The following is a quotation of the second paragraph of 35 U.S.C. 112:

The specification shall conclude with one or more claims particularly pointing out and distinctly claiming the subject matter which the applicant regards as his invention.

4. Claims 1-40 are rejected under 35 U.S.C. 112, second paragraph, as being indefinite for failing to particularly point out and distinctly claim the subject matter which applicant regards as the invention.

Claim 1 is vague and indefinite because it is unclear how the homogenized sample is substantially free of nonpathogenic prion protein. The specification on page 4

discloses that treating the sample with proteinase-K digests substantially all the nonpathogenic prion protein in the sample. It is unclear if the homogenized sample comprises proteinase-K which has substantially digested all nonpathogenic prion protein or if the nonpathogenic prion protein is removed before being subjected to proteinase-K. Please clarify.

Claim 1 is vague and indefinite because it is unclear how the membrane is associated with the proteinase-K support. Is the proteinase-K on the entire support and the membrane overlying the support? What exact relationship exists between the membrane and the proteinase-K support.

Claim 1, part (b) the recitation "substantially" is vague and indefinite. It is unclear what is considered to be substantial. There is no definition provided for the term in the specification. See also deficiency found in claim 16.

Claim 4 is vague and indefinite because it is unclear if the sample comprises the at least one emulsifier or surfactant, casein, at least one polysaccharide, albumin, and a sufficient quantity of water to form a mixture or if the buffer comprises the at least one emulsifier or surfactant, casein, at least one polysaccharide, albumin, and a sufficient quantity of water to form a mixture.

Claim 5 the recitation "polyoxyethylene (10) isooctylphenyl ether" is vague and indefinite because it is unclear if the recitation contained within the parenthesis is part of the claim or not. See also deficiency found in claim 23

Claim 11 is vague and indefinite because the preamble of the claim does not correlate with the body of the claim. The preamble of the claim recites determining the

Art Unit: 1641

presence of pathogenic prion protein whereas the body of the claim recites interpreting the response to indicate the presence or concentration of the pathogenic prion protein.

See also deficiency found in claim 28.

Claim 16, line 1 the recitation "sufficient" is vague and indefinite. It is unclear what is considered to be sufficient. There is no definition provided for the term in the specification.

Claim 16 the recitation "digest substantially all protein in the sample" is vague and indefinite because it is unclear if all the protein includes the pathogenic prion protein. Further, if it includes the pathogenic prion protein it is unclear how the protein is detected if it is digested.

Claim 18 is vague and indefinite because it is unclear if the enzyme is referring to the proteinase K or to some other enzyme. Please clarify.

Claim 18, the recitation "the solid support" there is insufficient antecedent basis for this limitation.

Claim 28, part (c) "enzymatic treatment" is vague and indefinite. It is unclear if applicant is referring to the proteinase-K or some other enzyme.

Claim 34 is vague and indefinite because it is unclear what animal part applicant is referring to.

Claim 34 is vague and indefinite because it is unclear how the animal part is designated for human consumption.

Claim 35, part (c) is vague and indefinite because it is unclear how the result is being obtained. Is applicant detecting the labeled antibody to determine the presence

Art Unit: 1641

or concentration of pathogenic prion or is applicant receiving the result from something else? Please clarify.

Claim 40, part (b) the recitation "the homogenized sample" there is insufficient antecedent basis for this limitation.

Claim 40, part (b) the recitation "the proteinase support" there is insufficient antecedent basis for this limitation.

Claim Rejections - 35 USC § 103

5. The following is a quotation of 35 U.S.C. 103(a) which forms the basis for all obviousness rejections set forth in this Office action:

(a) A patent may not be obtained though the invention is not identically disclosed or described as set forth in section 102 of this title, if the differences between the subject matter sought to be patented and the prior art are such that the subject matter as a whole would have been obvious at the time the invention was made to a person having ordinary skill in the art to which said subject matter pertains. Patentability shall not be negated by the manner in which the invention was made.

6. The factual inquiries set forth in *Graham v. John Deere Co.*, 383 U.S. 1, 148 USPQ 459 (1966), that are applied for establishing a background for determining obviousness under 35 U.S.C. 103(a) are summarized as follows:

1. Determining the scope and contents of the prior art.
2. Ascertaining the differences between the prior art and the claims at issue.
3. Resolving the level of ordinary skill in the pertinent art.
4. Considering objective evidence present in the application indicating obviousness or nonobviousness.

7. This application currently names joint inventors. In considering patentability of the claims under 35 U.S.C. 103(a), the examiner presumes that the subject matter of the various claims was commonly owned at the time any inventions covered therein were made absent any evidence to the contrary. Applicant is advised of the obligation under 37 CFR 1.56 to point out the inventor and invention dates of each claim that was

Art Unit: 1641

not commonly owned at the time a later invention was made in order for the examiner to consider the applicability of 35 U.S.C. 103(c) and potential 35 U.S.C. 102(e), (f) or (g) prior art under 35 U.S.C. 103(a).

8. Claims 1-3, 7-17, 19, 27, 28, 32-36 and 40 are rejected under 35 U.S.C. 103(a) as being unpatentable over Schmerr et al (US 6,150,172) in view of Sundrehagen (WO 00/36418) and further in view of Pugia et al (US 5,846,754).

Schmerr et al disclose methods for selectively detecting abnormal prion protein in a sample. Schmerr et al disclose that the detection can be performed by immunoassays such as ELISA and sandwich immunoassays (col 8-10). Schmerr et al specifically teaches that extraction solvent containing any prion protein can be applied to an immunochromatographic membrane or support (col 10, lines13-25). Schmerr et al disclose the use of antibodies in these immunoassays. Schmerr et al disclose that the detection can be performed using an immunochromatographic membrane or support (test device). Schmerr et al disclose that the sample can be a biological sample or products made from animal organs or tissues such as food and processed food products (col 5). Schmerr et al disclose that the sample can be homogenized (col 5). Schmerr et al disclose treating the sample with proteinase K to digest the normal host prion. Schmerr et al also disclose the extraction of prion protein into a buffered medium. Schmerr et al disclose that abnormal prion proteins include proteins found in transmissible spongiform encephalopathy, Kuru and Creutzfeld-Jakob Disease (col 6).

Schmerr et al differ from the instant invention in failing to teach the specifics of the immunochromatographic membrane (test device).

Sundrehagen (WO 00/36418) disclose a test device for detecting and quantifying the content of analyte in a sample. Sundrehagen disclose that the test device comprises a sample pad, which comprises a reagent for removing variants of analyte which are not desired to be detected. Sundrehagen disclose that the test strip also comprises a conjugate pad having a labeled first antibody and a detection pad (test strip) comprising an immobilized second antibody (Fig. 1). Sundrehagen disclose that detection can be visual or with the aid of instrumentation (p. 25-26). Sundrehagen also discloses the use of a calibration curve to determine the analyte (p. 31).

It would have been obvious to one of ordinary skill in the art to use the test device taught by Sundrehagen in the method of Schmerr et al because Schmerr et al specifically teaches the advantages of using test strips and Sundrehagen et al shows that their device provides for different variant forms of an analyte to be discriminated and that by measuring different variants of a protein in a sample of interest, a diagnosis or assessment of a disease or cellular damage can be made.

Schmerr et al and Sundrehagen et al differ from the instant invention in failing to teach proteinase-K immobilized in the test device.

Pugia et al (US 5,846,754) disclose impregnating an enzyme in a test strip (col 4).

It also would have been obvious to one of ordinary skill in the art to immobilize proteinase-K in the device of Sundrehagen for use in the method of Schmerr et al because Schmerr et al teaches proteinase-K to remove undesired proteins from the sample and Sundrehagen et al teaches immobilized reagents in the test device to remove variants of analyte which are not desired to be detected and Pugia et al teaches

Art Unit: 1641

that it is known in the art to immobilize enzymes to a test device prior to the addition of sample. Therefore, it would have been obvious to one of ordinary skill in the art to immobilize proteinase-K in the device of Sundrehagen for use in the method of Schmerr et al. Further, the immobilization of proteinase-K on the test device provides that advantage of having one less preparation step of the sample.

With respect to the response produced within from about 0.5 to 20 minutes after the sample is applied to the test device. Since, the modified method and device of Schmerr et al comprises the same test device and reagents as instantly recited one of ordinary skill in the art would expect the response to be produced within the time as instantly recited.

9. Claims 6, 18, 20, 21, 29, 30, 38, and 39 are rejected under 35 U.S.C. 103(a) as being unpatentable over Schmerr et al (US 6,150,172) in view of Sundrehagen (WO 00/36418) and further in view of Puglia et al (US 5,846,754).

See above for teachings of Schmerr et al, Sundrehagen and Puglia et al.

Schmerr et al, Sundrehagen and Puglia et al differ from the instant invention in failing to teach the buffer is an aqueous solution with an ionic strength of from about 200 to about 400 nM. Schmerr et al, Sundrehagen and Puglia et al also fail to teach the amount of enzyme on the solid support and the weight/volume ratio of sample to buffer.

With respect to the ionic strength of the buffer solution as recited in the instant claims, the optimum ionic strength can be determined by routine experimentation and thus would have been obvious to one of ordinary skill in the art. Further, It has long been settled to be no more than routine experimentation for one of ordinary skill in the art to discover an optimum value of

Art Unit: 1641

a result effective variable. “[W]here the general conditions of a claim are disclosed in the prior art, it is not inventive to discover the optimum of workable ranges by routine experimentation.”

Application of *Aller*, 220 F.2d 454,456, 105 USPQ 233, 235-236 (C.C.P.A. 1955). “No invention is involved in discovering optimum ranges of a process by routine experimentation.”

Id. At 458,105 USPQ at 236-237. The “discovery of an optimum value of a result effective variable in a known process is ordinarily within the skill of the art.” Application of *Boesch*, 617 F.2d 272,276, 205 USPQ 215, 218-219 (C.C.P.A. 1980).

With respect to the buffer in a weight/volume ratio of sample to buffer as recited in the instant claims the optimum weight/volume ratio of sample to buffer can be determined by routine experimentation and thus would have been obvious to one of ordinary skill in the art. Further, It has long been settled to be no more than routine experimentation for one of ordinary skill in the art to discover an optimum value of a result effective variable. “[W]here the general conditions of a claim are disclosed in the prior art, it is not inventive to discover the optimum of workable ranges by routine experimentation.” Application of *Aller*, 220 F.2d 454,456, 105 USPQ 233, 235-236 (C.C.P.A. 1955). “No invention is involved in discovering optimum ranges of a process by routine experimentation .” *Id.* At 458,105 USPQ at 236-237. The “discovery of an optimum value of a result effective variable in a known process is ordinarily within the skill of the art.” Application of *Boesch*, 617 F.2d 272,276, 205 USPQ 215, 218-219 (C.C.P.A. 1980).

With respect to the amount of enzyme on the solid support as recited in the instant claims the optimum amount of enzyme on the solid support can be determined by routine experimentation and thus would have been obvious to one of ordinary skill in the art. Further,

Art Unit: 1641

It has long been settled to be no more than routine experimentation for one of ordinary skill in the art to discover an optimum value of a result effective variable. “[W]here the general conditions of a claim are disclosed in the prior art, it is not inventive to discover the optimum of workable ranges by routine experimentation.” Application of Aller, 220 F.2d 454,456, 105 USPQ 233, 235-236 (C.C.P.A. 1955). “No invention is involved in discovering optimum ranges of a process by routine experimentation .” Id. At 458,105 USPQ at 236-237. The “discovery of an optimum value of a result effective variable in a known process is ordinarily within the skill of the art.” Application of Boesch, 617 F.2d 272,276, 205 USPQ 215, 218-219 (C.C.P.A. 1980).

Allowable Subject Matter

10. Claims 4, 5, 22-26, 31 and 37 would be allowable if rewritten to overcome the rejection(s) under 35 U.S.C. 112, second paragraph, set forth in this Office action and to include all of the limitations of the base claim and any intervening claims.

11. The following is a statement of reasons for the indication of allowable subject matter: the prior art of record neither teaches nor suggests methods for detecting prion protein wherein at least four elements comprised in the buffer for homogenizing the sample (i.e. at least one surfactant or emulsifier, at least one polysaccharide, casein and albumin).

Conclusion

12. The prior art made of record and not relied upon is considered pertinent to applicant's disclosure.

Daniels et al., (2002/0004246) disclose a test device and also disclose the treatment of sample with proteinase K (page 6, para. 93).

Vallari et al., (5,922,533) disclose a test device having a conjugate pad disposed between a sample pad and the test strip (Fig. 13).

Sundrehagen (US 6,716,641) disclose a test device for detecting and quantifying the content of a target analyte in a sample.

Randolph et al., (US 2004/0038333) disclose buffering agent for homogenizing a sample (p. 6 and p. 8).

Aslamkhan et al., (US 2003/0044868) disclose homogenization buffer (p. 5).

Any inquiry concerning this communication or earlier communications from the examiner should be directed to Gary W. Counts whose telephone number is (571) 2720817. The examiner can normally be reached on M-F 8:00 - 4:30.

If attempts to reach the examiner by telephone are unsuccessful, the examiner's supervisor, Long Le can be reached on (571) 272-0823. The fax phone number for the organization where this application or proceeding is assigned is 703-872-9306.

Information regarding the status of an application may be obtained from the Patent Application Information Retrieval (PAIR) system. Status information for published applications may be obtained from either Private PAIR or Public PAIR. Status information for unpublished applications is available through Private PAIR only. For more information about the PAIR system, see <http://pair-direct.uspto.gov>. Should you have questions on access to the Private PAIR system, contact the Electronic Business Center (EBC) at 866-217-9197 (toll-free).

Art Unit: 1641



Gary W. Counts
Examiner
Art Unit 1641
April 14, 2004



LONG V. LE
SUPERVISORY PATENT EXAMINER
TECHNOLOGY CENTER 1600

04/21/04